Current Landscape of Chinese Drug Research and US Lawmakers' Impact on China Biotech
Chinese Drug Research and Its Resilience
Wuxi AppTec has reported a surge in orders for drug development amidst increasing scrutiny from US lawmakers regarding China biotech. The company’s primary chemistry business remains robust, reflecting a healthy influx of new projects with its customer base expanding throughout the first half of 2024.
Impact of US Legislation on China Biotech
The approach by US lawmakers to sever ties with Chinese service providers comes as Wuxi AppTec’s stock hits record highs. Morgan Stanley analysts, led by Sean Wu, have shown confidence in Wuxi’s ability to thrive despite macroeconomic challenges, highlighting the company’s solid order growth.
Global Biotech Funding Trends
Despite the turbulence, the rise of global biotech funding and enhanced recognition of China biotech on the international stage demonstrate enduring opportunities for Wuxi. The firm is making strides in areas such as oligonucleotides and peptides, especially with the increasing popularity of GLP-1 drugs.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.